Drug Trial Radar · NCT05192941
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
Last checked: Nov 20, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,770
Actual
Start
Apr 8, 2022
Primary completion
Jun 11, 2024
Study completion Mar 19, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study of efficacy, safety, tolerability and quality of life of inclisiran (KJX839) vs placebo, on top of ongoing individually optimized lipid-lowering therapy, in participants with hypercholesterolemia
Conditions
- Hypercholesterolemia
Interventions
Inclisiran SodiumDrug
Subcutaneously injected on Day 1, Day 90, and Day 270
PlaceboDrug
Placebo to inclisiran 300 mg subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Achieving Individual LDL-C Target (<55 mg/dL or <70 mg/dL)Time frame: Day 90
Locations
136 sites in 8 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Burgas, Bulgaria
Novartis Investigative Site
Gabrovo, Bulgaria
Novartis Investigative Site
Pleven, Bulgaria
Novartis Investigative Site
Plovdiv, Bulgaria
Novartis Investigative Site
Rousse, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Stara Zagora, Bulgaria
Novartis Investigative Site
Varna, Bulgaria
Novartis Investigative Site
Veliko Tarnovo, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria, Bulgaria
Novartis Investigative Site
Burgas, Burgas, Bulgaria
Novartis Investigative Site
Hlučín, Czechia
Novartis Investigative Site
Hodonín, Czechia
Novartis Investigative Site
Mělník, Czechia
Novartis Investigative Site
Olomouc, Czechia
Novartis Investigative Site
Olomouc, Czechia
Novartis Investigative Site
Pardubice, Czechia
Novartis Investigative Site
Slaný, Czechia
Novartis Investigative Site
Trutnov, Czechia
Novartis Investigative Site
Chlumec nad Cidlinou, Chlumec Nad Cidlinou, Czechia
Novartis Investigative Site
Přerov, Olomouc Region, Czechia
Novartis Investigative Site
Pärnu, Estonia
Novartis Investigative Site
Tallinn, Estonia
Novartis Investigative Site
Tallinn, Estonia
Novartis Investigative Site
Tartu, Estonia
Novartis Investigative Site
Amiens, France
Novartis Investigative Site
Chambéry, France
Novartis Investigative Site
Le Chesnay, France
Novartis Investigative Site
Le Kremlin-Bicêtre, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Nantes, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Valenciennes, France
Novartis Investigative Site
Bad Homburg, Germany
Novartis Investigative Site
Bad Krozingen, Germany
Novartis Investigative Site
Bad Oeynhausen, Germany
Novartis Investigative Site
Bamberg, Germany
Showing 40 of 136 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.